GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...